Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused… Read More..

Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index (CDLQI) all demonstrated improvement from baseline QRX003 is being well tolerated and no adverse events have been… Read More..

MIAMI, May 13, 2025 (GLOBE NEWSWIRE) -- SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 97 issued and pending patents globally and a portfolio of over 60 lighting and home décor websites, announced today that… Read More..